PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16189829-4 2005 Combining fluorescence spectroscopy, immunocytochemistry, microarrays, RT-PCR and MTT, several important events of the insulin signaling pathways were investigated, including ligand-receptor binding capacity, intracellular tyrosine phosphorylation level, gene transcription, and cell proliferation. monooxyethylene trimethylolpropane tristearate 82-85 insulin Homo sapiens 119-126 18241547-3 2007 The effects of insulin at different concentrations and different time on proliferation, apoptosis and cell cycle distribution of endometrial carcinoma cells were observed by methyl thiazolyl tetrazolium (MTT) assay and fluorescence-activated cell sorting technique. monooxyethylene trimethylolpropane tristearate 204-207 insulin Homo sapiens 15-22 17439729-2 2007 METHODS: The effect of insulin/5-FU combination treatment on the growth of Eca 109 and Ls-174-t cells was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. monooxyethylene trimethylolpropane tristearate 182-185 insulin Homo sapiens 23-30 11348451-6 2001 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays showed significantly higher values in cultured skin substitutes incubated with insulin at incubation days 14 and 28 compared to negative control or the 10 ng per ml insulin-like growth factor I condition. monooxyethylene trimethylolpropane tristearate 63-66 insulin Homo sapiens 154-161 16155268-4 2005 RESULTS: When assessed by euglycemic-hyperinsulinemic clamp, insulin sensitivity was higher after resistant starch supplementation than after placebo treatment (9.7 and 8.5 x 10(-2) mg glucose x kg(-1) x min(-1) x (mU insulin/L)(-1), respectively; P = 0.03); insulin sensitivity during the meal tolerance test (MTT) was 33% higher (P = 0.05). monooxyethylene trimethylolpropane tristearate 311-314 insulin Homo sapiens 61-68 16155268-4 2005 RESULTS: When assessed by euglycemic-hyperinsulinemic clamp, insulin sensitivity was higher after resistant starch supplementation than after placebo treatment (9.7 and 8.5 x 10(-2) mg glucose x kg(-1) x min(-1) x (mU insulin/L)(-1), respectively; P = 0.03); insulin sensitivity during the meal tolerance test (MTT) was 33% higher (P = 0.05). monooxyethylene trimethylolpropane tristearate 311-314 insulin Homo sapiens 61-68 15285037-6 2004 Cytoreductive effect of insulin-MTX on human hepatoma BEL7402 cells and human hepatocyte cell line HL7702 was evaluated using the MTT assay. monooxyethylene trimethylolpropane tristearate 130-133 insulin Homo sapiens 24-31 12812659-10 2003 Insulin (2.0 - 15.0 mU/ml) enhanced the chemocytotoxity of etopside (30 micro g/ml) on human esophageal and lung cancer cells as indicated by MTT colorimetry. monooxyethylene trimethylolpropane tristearate 142-145 insulin Homo sapiens 0-7 11788647-8 2002 It was possible to explain 70-80% interindividual variability of fasting plasma glucose, FPI, HbA(1C), and insulin responses to MTT, and only 25-40% interindividual variability of postprandial glucose. monooxyethylene trimethylolpropane tristearate 128-131 insulin Homo sapiens 107-114 11348451-7 2001 Cultured skin substitutes incubated in 50 ng per ml insulin-like growth factor I had MTT values similar to the insulin-treated cultured skin substitutes at day 14, but were significantly lower by day 28. monooxyethylene trimethylolpropane tristearate 85-88 insulin Homo sapiens 52-59 11348451-8 2001 Light microscopy agreed with MTT data showing that cultured skin substitutes grown with insulin media had multiple layers of nucleated keratinocytes and stratum corneum at days 14 and 28. monooxyethylene trimethylolpropane tristearate 29-32 insulin Homo sapiens 88-95 8026282-7 1994 Insulin therapy reduced maternal capillary (P < 0.005) and MTT (P < 0.001) glucose levels and prevented a diet-associated rise in MTT triglyceride levels (P < 0.002). monooxyethylene trimethylolpropane tristearate 62-65 insulin Homo sapiens 0-7 8894476-3 1996 A deficient early (first hour) post-prandial (MTT) insulin secretion was demonstrated in all NIDDM patients, deteriorating with increasing fasting hyperglycaemia. monooxyethylene trimethylolpropane tristearate 46-49 insulin Homo sapiens 51-58 1817807-5 1991 Insulin was given by intravenous infusion (2.5 U Actrapid over 30 min) immediately following the start of a 500 kcal MTT. monooxyethylene trimethylolpropane tristearate 117-120 insulin Homo sapiens 0-7 1601998-6 1992 The lowered area under the insulin curve during oGTT and MTT as a result of the administration of rhIGF-I were related to the fasting insulin levels during saline infusion (oGTT: r = 0.825, P less than 0.05; MTT: r = 0.895, P less than 0.02). monooxyethylene trimethylolpropane tristearate 57-60 insulin Homo sapiens 134-141 1601998-6 1992 The lowered area under the insulin curve during oGTT and MTT as a result of the administration of rhIGF-I were related to the fasting insulin levels during saline infusion (oGTT: r = 0.825, P less than 0.05; MTT: r = 0.895, P less than 0.02). monooxyethylene trimethylolpropane tristearate 208-211 insulin Homo sapiens 27-34 1601998-6 1992 The lowered area under the insulin curve during oGTT and MTT as a result of the administration of rhIGF-I were related to the fasting insulin levels during saline infusion (oGTT: r = 0.825, P less than 0.05; MTT: r = 0.895, P less than 0.02). monooxyethylene trimethylolpropane tristearate 208-211 insulin Homo sapiens 134-141 1547676-9 1992 MTT levels of insulin, free fatty acids, and glucagon were significantly lower after treatment. monooxyethylene trimethylolpropane tristearate 0-3 insulin Homo sapiens 14-21 33776619-6 2021 The patients with needed insulin therapy had significantly higher fasting PG levels in the 75-g OGTT, PG levels at fasting and 30 min after the MTT, and homeostasis model assessment of insulin resistance (HOMA-IR), and a significantly lower disposition index (DI) and insulin index than patients treated by diet alone. monooxyethylene trimethylolpropane tristearate 144-147 insulin Homo sapiens 25-32 33776619-7 2021 Receiver operating characteristic curve analysis was performed for factors involved in insulin therapy, with the following cutoff values: fasting PG in the 75-g OGTT, 92 mg/dL; PG 30 min after MTT, 129 mg/dL; HOMA-IR, 1.51; DI, 3.9; HbA1c, 5.4%. monooxyethylene trimethylolpropane tristearate 193-196 insulin Homo sapiens 87-94 33776619-8 2021 Multivariate analysis revealed that the 30-min PG level after MTT and HOMA-IR predicted insulin therapy. monooxyethylene trimethylolpropane tristearate 62-65 insulin Homo sapiens 88-95 33776619-9 2021 Conclusion: PG levels at 30 min after MTT may be useful for identifying patients with GDM, who need insulin therapy. monooxyethylene trimethylolpropane tristearate 38-41 insulin Homo sapiens 100-107 35082201-8 2022 The postprandial hypertriglyceridemia induced by the MTT was associated with insulin resistance, but it was not associated with the impaired insulinogenic index or the disposition index. monooxyethylene trimethylolpropane tristearate 53-56 insulin Homo sapiens 77-84 35082201-9 2022 These results indicate that the new MTT is clinically useful to evaluate both abnormal glucose and triglyceride excursions caused by abnormal insulin sensitivity and secretions of insulin and gut hormones in morbidly obese patients. monooxyethylene trimethylolpropane tristearate 36-39 insulin Homo sapiens 142-149 35082201-9 2022 These results indicate that the new MTT is clinically useful to evaluate both abnormal glucose and triglyceride excursions caused by abnormal insulin sensitivity and secretions of insulin and gut hormones in morbidly obese patients. monooxyethylene trimethylolpropane tristearate 36-39 insulin Homo sapiens 180-187 3056813-9 1988 Proinsulin has a mean transit time (MTT) of 322 minutes. monooxyethylene trimethylolpropane tristearate 36-39 insulin Homo sapiens 0-10 3056813-10 1988 This is longer than the MTT of normal insulin (188 minutes) but markedly shorter than that of NPH insulin (625 minutes). monooxyethylene trimethylolpropane tristearate 24-27 insulin Homo sapiens 38-45 32475902-7 2021 At the end of monotherapy, insulin secretion relative to glucose elevation (ISG0-30: area under the curve of insulin from 0 to 30 min during MTT [AUC0-30 of IRI]/AUC0-30 of plasma glucose) was significantly increased only in the repaglinide group; ISG0-30 did not significantly increase in either group after the addition of alogliptin.ConclusionsThe addition of alogliptin to repaglinide monotherapy did not cause glucose-independent inappropriate insulin secretion and did not appear to increase the incidence of hypoglycemia. monooxyethylene trimethylolpropane tristearate 141-144 insulin Homo sapiens 109-116 32152803-10 2020 The biological activity of human insulin was tested in vitro using a MTT assay, which revealed that the crude biosynthesised human insulin displayed a similar degree of efficacy to the standard human insulin. monooxyethylene trimethylolpropane tristearate 69-72 insulin Homo sapiens 33-40 32152803-10 2020 The biological activity of human insulin was tested in vitro using a MTT assay, which revealed that the crude biosynthesised human insulin displayed a similar degree of efficacy to the standard human insulin. monooxyethylene trimethylolpropane tristearate 69-72 insulin Homo sapiens 131-138 32152803-10 2020 The biological activity of human insulin was tested in vitro using a MTT assay, which revealed that the crude biosynthesised human insulin displayed a similar degree of efficacy to the standard human insulin. monooxyethylene trimethylolpropane tristearate 69-72 insulin Homo sapiens 131-138 32938850-10 2020 The patients who needed insulin therapy at 6 months after hospitalization showed a significant lower incremental CPR value from 0 to 120 minutes in the MTT than those who did not need insulin therapy. monooxyethylene trimethylolpropane tristearate 152-155 insulin Homo sapiens 24-31 28320046-1 2018 OBJECTIVE: To assess insulin sensitivity in patients with systemic lupus erythematosus (SLE) in response to a meal tolerance test (MTT). monooxyethylene trimethylolpropane tristearate 131-134 insulin Homo sapiens 21-28 30168485-4 2018 Methods: The effect of human insulin and S961 on growth, proliferation rate and clonogenic potential of breast cancer cells was evaluated by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide] assay and clonogenic assay. monooxyethylene trimethylolpropane tristearate 141-144 insulin Homo sapiens 29-36 29982277-9 2018 Indexes of insulin sensitivity and secretion were significantly improved for the second CP MTT. monooxyethylene trimethylolpropane tristearate 91-94 insulin Homo sapiens 11-18 25967609-3 2015 Moreover, cytotoxicity of aggregated insulin was monitored on SH-SY5Y cell line in the presence and absence of black seeds extract using standard 3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide (MTT), lactate dehydrogenase (LDH) and reactive oxygen species (ROS) assay kit. monooxyethylene trimethylolpropane tristearate 208-211 insulin Homo sapiens 37-44 27104558-6 2016 Unexpectedly, our results indicated that insulin protected hepatocytes against SFA-induced lipotoxicity, based on the LDH, MTT, and nuclear morphological measurements, and the detection from cleaved-Parp-1 and -caspase-3 expressions. monooxyethylene trimethylolpropane tristearate 123-126 insulin Homo sapiens 41-48 25166626-6 2014 Using repeated-measures linear mixed models, area under the curve of plasma glucose or insulin after the MTT was not different between conditions. monooxyethylene trimethylolpropane tristearate 105-108 insulin Homo sapiens 87-94 25613093-6 2015 Linear regression analyses revealed that glucose area under the curve (AUC)0-120 min was associated with glucagon-AUC0-30 min and insulin-AUC0-30 min in both OGTT and MTT. monooxyethylene trimethylolpropane tristearate 167-170 insulin Homo sapiens 130-137 23904152-10 2013 Insulin-dependent glucose clearance for the HGC was about 3-fold greater than for the MTT (0.0111 vs. 0.00425 L/min/[mU/L]). monooxyethylene trimethylolpropane tristearate 86-89 insulin Homo sapiens 0-7 24940825-4 2014 The dose used for the MTT was individually calculated based on the prandial insulin records from the patient diaries before the test. monooxyethylene trimethylolpropane tristearate 22-25 insulin Homo sapiens 76-83 24940825-8 2014 The prandial insulin dose decreased in the MTT modulation device group by -17.1%, but remained unchanged in the control group (-0.1%, p < 0.001). monooxyethylene trimethylolpropane tristearate 43-46 insulin Homo sapiens 13-20 23579178-7 2013 The increase in mean post-MTT plasma insulin and in ISR was similar in P, M, and S and slightly greater in M+S. monooxyethylene trimethylolpropane tristearate 26-29 insulin Homo sapiens 37-44 24373396-6 2013 (2) MTT results showed that insulin glargine could inhibit the proliferation of omental preadipocytes in a dose-dependent fashion. monooxyethylene trimethylolpropane tristearate 4-7 insulin Homo sapiens 28-35 22446171-6 2012 In contrast, the MTT incremental area under the curve (iAUC) for both glucose (from 249.3 +- 28.5 to 198.8 +- 23.6 mmol/L min, P < 0.01) and insulin (from 20,130 [13,542-35,292] to 13,086 [9,804-21,138] pmol/L min, P < 0.05) decreased with colesevelam. monooxyethylene trimethylolpropane tristearate 17-20 insulin Homo sapiens 146-153 23339473-1 2013 BACKGROUND: We developed a simple and new insulin resistance index derived from a glucose clamp and a meal tolerance test (MTT) in Japanese patients with type 2 diabetes mellitus. monooxyethylene trimethylolpropane tristearate 123-126 insulin Homo sapiens 42-49 20981457-5 2013 With such cutoffs, S I-MTT < 6.3 min(-1)/(muU/ml) 10(-4) with Caumo"s OMM was the best predictor of insulin resistance defined as S I-IVGTT < 2 min(-1)/(muU/ml) 10(-4). monooxyethylene trimethylolpropane tristearate 23-26 insulin Homo sapiens 103-110 23811986-9 2013 First, we used the area under the insulin curve (AUC(IN)) during MTT to quantify the 2nd ISEC. monooxyethylene trimethylolpropane tristearate 65-68 insulin Homo sapiens 34-41 20450582-2 2010 METHODS: MTT assay was used to examine the inhibition rate of cell growth after treatment with 5-Fu and insulin. monooxyethylene trimethylolpropane tristearate 9-12 insulin Homo sapiens 104-111 19115062-3 2009 MTT-based colorimetric methods demonstrated that insulin enhances proliferation and survival of HUVECs. monooxyethylene trimethylolpropane tristearate 0-3 insulin Homo sapiens 49-56